Download PDF
Thromb Haemost 1969; 21(01): 134-143
DOI: 10.1055/s-0038-1653516
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

Plasma Fibrin Stabilising Factor (F. S. F.) Activity in Normal Subjects and Patients with Chronic Liver Disease

W. D Walls
1   Department of Medicine, The University of Leeds, The General Infirmary, Leeds, 1
,
M. S Losowsky
1   Department of Medicine, The University of Leeds, The General Infirmary, Leeds, 1
› Author Affiliations
Further Information

Publication History

Publication Date:
10 June 2018 (online)

    Permissions and Reprints

Summary

A kinetic method for the quantitative estimation of plasma F.S.F. activity is described and discussed.

This method was applied to normal subjects and to patients with chronic liver disease. The plasma F.S.F. activity was uninfluenced by either sex or age, and the normal range has been defined.

A significant decrease in plasma F.S.F. activity was observed in patients with chronic liver disease. Subnormal levels of activity were found in 25% of such patients but were unrelated to episodes of abnormal haemorrhage. Plasma F.S.F. activity tended to be lower in patients with disease of greater clinical severity. In 2 patients showing clinical improvement there was an increase in plasma F. S. F. activity.

It was confirmed that plasma fibrinogen levels increase with age.

 

  • References

  • 1 Bouhasin J. D, Altay G. Factor XIII deficiency: Concentrations in relatives of patients and in normal infants. J. Pediatrics 72: 336-341 1968;
    CrossrefPubMedGoogle Scholar
  • 2 Britten A. F. H. Congenital deficiency of factor XIII (fibrinstabilizing factor). Amer. J. Med 43: 751-761 1967;
    CrossrefPubMedGoogle Scholar
  • 3 Duckert F. The therapy of factor XIII deficiency. Proc. 10th Congr. int. Soc. Blood Transf., Stockholm 1964 08: 1354-1357 1965;
    PubMedGoogle Scholar
  • 4 Gerhold W. M, Tiongson T, Mandel E. E. Studies of fibrinstabilizing factor. Fed. Proc 25: 446 1966;
    PubMedGoogle Scholar
  • 5 Jacobsson K. Studies on the determination of fibrinogen in human blood plasma. Scand. J. clin. Lab. Invest 07 Suppl. 4 1955;
    PubMedGoogle Scholar
  • 6 Kunzer W, Lutgemeier J. Zur entwicklungsbedingten Abhängigkeit des Plasmagehaltes an Fibrin-stabilisierendem Faktor (F.S.F.). Ann. Paediat 204: 232-238 1965;
    PubMedGoogle Scholar
  • 7 Laki K, Lorand L. On the solubility of fibrin clots. Science 108: 280 1948;
    CrossrefPubMedGoogle Scholar
  • 8 Loewy A. G, Dahlberg J. E, Dorwart Jr W. V, Weber M. J, Eisele J. A transamidase mechanism for insoluble fibrin formation. Biochem. biophys. Res. Commun 15: 177-181 1964;
    CrossrefPubMedGoogle Scholar
  • 9 Loewy A. G, Matacic S, Darnell J. H. Transamidase activity of the enzyme responsible for insoluble fibrin formation. Arch. Biochem 113: 435-438 1966;
    CrossrefPubMedGoogle Scholar
  • 10 Lorand L, Ghen C. H, Fuchs L. E, Jacobsen A, Lorand J. B. A plasma globulin as a partner of fibrin in clot formation. Proc. of the Fourth International Congress of Biochemistry 10: 228-238 1958;
    PubMedGoogle Scholar
  • 11 Lorand L, Dickenman R. G. Assay method for the “fibrinstabilizing factor”. Proc. Soc. exp. Biol. (N. Y) 89: 45-48 1955;
    CrossrefPubMedGoogle Scholar
  • 12 Lorand L, Jacobsen A. Specific inhibitors and the chemistry of fibrin polymerisation. Biochemistry 03: 1939-1943 1964;
    CrossrefPubMedGoogle Scholar
  • 13 Lorand L, Konishi K. Activation of fibrin-stabilizing factor of plasma by thrombin. Arch. Biochem 105: 58-67 1964;
    CrossrefPubMedGoogle Scholar
  • 14 Losowsky M. S, Hall B. Estimation of plasma fibrin-stabilizing factor in families showing congenital deficiencies. Clin. Sei 30: 171-178 1966;
    PubMedGoogle Scholar
  • 15 Mandelli F, Morelli R, Fontana L, Schettini G. C, De Lorenzi A. Comportamento del fattore stabilizzante fibrinico nelle neoplasie di varia origine. Gass. Inter, di Med. e Chir 70: 1133-1142 1965;
    PubMedGoogle Scholar
  • 16 Morse B. S, Nussbaum M. Effect of mercury on fibrin stabilizing factor (F.S.F.) and clot lysis. Clin. Res 11: 197 1963;
    PubMedGoogle Scholar
  • 17 Nussbaum M, Morse B. S. Plasma fibrin stabilizing factor activity in various diseases. Blood 23: 669-677 1964;
    PubMedGoogle Scholar
  • 18 Ogston G. M, Ogston D. Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease. J. clin. Path 19: 352-356 1966;
    CrossrefPubMedGoogle Scholar
  • 19 Ottaviani P, Mandelli F, Fontana L, Morelli R. II fattore stabilizzante fibrinico di Laki e Lorand nelle sarcometosi istio citarie a tendenza sistemica. Progr. Med 21: 10-13 1965;
    PubMedGoogle Scholar
  • 20 Ottaviani P, Mandelli F, Fontana L, Morelli R. Comportemento del fattore stabilizzante fibrinico nelle epatopatie. Progr. Med 21: 115-120 1965;
    PubMedGoogle Scholar
  • 21 Robbins K. C. A study of the conversion of fibrinogen to fibrin. Amer. J. Physiol 142: 581-588 1944;
    PubMedGoogle Scholar
  • 22 Shmerling D. H, Jung E, Duckert F. Eine neue familiäre Koagulopathie infolge Mangels an Fibrin-stabilisierendem Faktor. Helv. paediat. Acta 05: 471-478 1960;
    PubMedGoogle Scholar
  • 23 Sigg P. E, Duckert F. Ein neuer Test zur Bestimmung des Fibrin-stabilisierenden Faktors. Schweiz, med. Wschr 93: 1455-1456 1963;
    PubMedGoogle Scholar
  • 24 Ströder J. Über den Fibrin-stabilisierenden Faktor (F.S.F) in den verschiedenen Lebensabschnitten und bei bestimmten Krankheiten des Kindes. Ann. Paediat 203: 393-400 1964;
    PubMedGoogle Scholar